Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Common Equity (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Common Equity for 11 consecutive years, with $22.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 25.37% year-over-year to $22.4 million, compared with a TTM value of $22.4 million through Sep 2025, down 25.37%, and an annual FY2024 reading of $25.8 million, up 321.62% over the prior year.
  • Common Equity was $22.4 million for Q3 2025 at Kiora Pharmaceuticals, up from $22.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $34.9 million in Q1 2024 and bottomed at $6.1 million in Q4 2023.
  • Average Common Equity over 5 years is $17.9 million, with a median of $15.3 million recorded in 2021.
  • The sharpest move saw Common Equity tumbled 39.35% in 2022, then soared 321.62% in 2024.
  • Year by year, Common Equity stood at $14.6 million in 2021, then decreased by 27.83% to $10.5 million in 2022, then tumbled by 41.93% to $6.1 million in 2023, then skyrocketed by 321.62% to $25.8 million in 2024, then fell by 13.0% to $22.4 million in 2025.
  • Business Quant data shows Common Equity for KPRX at $22.4 million in Q3 2025, $22.1 million in Q2 2025, and $23.7 million in Q1 2025.